Stryka 969
Alternative Names: S-969; Stryka-969Latest Information Update: 28 Oct 2024
At a glance
- Originator University of Nevada Reno
- Developer Strykagen
- Class Small molecules
- Mechanism of Action Integrin alpha7beta1 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Duchenne muscular dystrophy; Limb girdle muscular dystrophies; Muscular dystrophies
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA (PO)
- 28 Oct 2024 No recent reports of development identified for preclinical development in Limb-girdle-muscular-dystrophies in USA (PO)
- 28 Oct 2024 No recent reports of development identified for preclinical development in Muscular-dystrophies in USA (PO)